Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study

Objective Aspirin may increase the risk of lower gastrointestinal bleeding (LGIB) from precursors of colorectal cancer (CRC). We investigated whether use of low-dose aspirin, through initiation of LGIB, may lead patients to undergo colonoscopy and polypectomy before manifest CRC.Design We conducted...

Full description

Bibliographic Details
Main Authors: Frederikke Schønfeldt Troelsen, Dóra Körmendiné Farkas, Rune Erichsen
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/7/1/e000453.full
id doaj-e81bbd984d724b5c9e58dd96d4bfcee4
record_format Article
spelling doaj-e81bbd984d724b5c9e58dd96d4bfcee42021-01-22T06:30:22ZengBMJ Publishing GroupBMJ Open Gastroenterology2054-47742020-11-017110.1136/bmjgast-2020-000453Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort studyFrederikke Schønfeldt Troelsen0Dóra Körmendiné Farkas1Rune Erichsen2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, DenmarkDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, DenmarkDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, DenmarkObjective Aspirin may increase the risk of lower gastrointestinal bleeding (LGIB) from precursors of colorectal cancer (CRC). We investigated whether use of low-dose aspirin, through initiation of LGIB, may lead patients to undergo colonoscopy and polypectomy before manifest CRC.Design We conducted a historical cohort study (2005–2013) of all Danish residents who initiated low-dose aspirin treatment (n=412 202) in a setting without screening for CRC. Each new aspirin user was matched with three non-users (n=1 236 560) by age, sex and region of residence on the date of their matched new user’s first-time aspirin prescription (index date). We computed absolute risks (ARs), risk differences and relative risks (RRs) of LGIB, lower gastrointestinal endoscopy, colorectal polyps and CRC, comparing aspirin users with non-users.Results The ARs were higher for new users than non-users for LGIB, lower gastrointestinal endoscopy, colorectal polyps and CRC within 3 months after index. Comparing new users with non-users, the RRs were 2.79 (95% CI 2.40 to 3.24) for LGIB, 1.73 (95% CI 1.63 to 1.84) for lower gastrointestinal endoscopy, 1.56 (95% CI 1.42 to 1.72) for colorectal polyps and 1.73 (95% CI 1.51 to 1.98) for CRC. The RRs remained elevated for more than 12 months after the index date, with the exception of CRC where the RRs were slightly decreased during the 3–5 years (RR 0.90, 95% CI 0.83 to 0.98) and more than 5 years (RR 0.91, 95% CI 0.82 to 1.00) following the index date.Conclusion These findings indicate that aspirin may contribute to reduce CRC risk by causing premalignant polyps to bleed, thereby expediting colonoscopy and polypectomy before CRC development.https://bmjopengastro.bmj.com/content/7/1/e000453.full
collection DOAJ
language English
format Article
sources DOAJ
author Frederikke Schønfeldt Troelsen
Dóra Körmendiné Farkas
Rune Erichsen
spellingShingle Frederikke Schønfeldt Troelsen
Dóra Körmendiné Farkas
Rune Erichsen
Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
BMJ Open Gastroenterology
author_facet Frederikke Schønfeldt Troelsen
Dóra Körmendiné Farkas
Rune Erichsen
author_sort Frederikke Schønfeldt Troelsen
title Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
title_short Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
title_full Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
title_fullStr Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
title_full_unstemmed Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study
title_sort risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a danish population-based cohort study
publisher BMJ Publishing Group
series BMJ Open Gastroenterology
issn 2054-4774
publishDate 2020-11-01
description Objective Aspirin may increase the risk of lower gastrointestinal bleeding (LGIB) from precursors of colorectal cancer (CRC). We investigated whether use of low-dose aspirin, through initiation of LGIB, may lead patients to undergo colonoscopy and polypectomy before manifest CRC.Design We conducted a historical cohort study (2005–2013) of all Danish residents who initiated low-dose aspirin treatment (n=412 202) in a setting without screening for CRC. Each new aspirin user was matched with three non-users (n=1 236 560) by age, sex and region of residence on the date of their matched new user’s first-time aspirin prescription (index date). We computed absolute risks (ARs), risk differences and relative risks (RRs) of LGIB, lower gastrointestinal endoscopy, colorectal polyps and CRC, comparing aspirin users with non-users.Results The ARs were higher for new users than non-users for LGIB, lower gastrointestinal endoscopy, colorectal polyps and CRC within 3 months after index. Comparing new users with non-users, the RRs were 2.79 (95% CI 2.40 to 3.24) for LGIB, 1.73 (95% CI 1.63 to 1.84) for lower gastrointestinal endoscopy, 1.56 (95% CI 1.42 to 1.72) for colorectal polyps and 1.73 (95% CI 1.51 to 1.98) for CRC. The RRs remained elevated for more than 12 months after the index date, with the exception of CRC where the RRs were slightly decreased during the 3–5 years (RR 0.90, 95% CI 0.83 to 0.98) and more than 5 years (RR 0.91, 95% CI 0.82 to 1.00) following the index date.Conclusion These findings indicate that aspirin may contribute to reduce CRC risk by causing premalignant polyps to bleed, thereby expediting colonoscopy and polypectomy before CRC development.
url https://bmjopengastro.bmj.com/content/7/1/e000453.full
work_keys_str_mv AT frederikkeschønfeldttroelsen riskoflowergastrointestinalbleedingandcolorectalneoplasmsfollowinginitiationoflowdoseaspirinadanishpopulationbasedcohortstudy
AT dorakormendinefarkas riskoflowergastrointestinalbleedingandcolorectalneoplasmsfollowinginitiationoflowdoseaspirinadanishpopulationbasedcohortstudy
AT runeerichsen riskoflowergastrointestinalbleedingandcolorectalneoplasmsfollowinginitiationoflowdoseaspirinadanishpopulationbasedcohortstudy
_version_ 1724328493566656512